Tirzepatide Recall 2026: Which Vials, and What to Do

Is tirzepatide being recalled? Some compounded tirzepatide is, but brand-name Zepbound and Mounjaro are not. In fall 2026, FDA enforcement reports listed Class II recalls of compounded tirzepatide from three pharmacies: Apothecary Pharma in North Carolina, Houston RX in Texas and Carolina Infusion in South Carolina. The reason in each case was a "lack of assurance of sterility." No illnesses tied to these vials have been publicly reported so far.

The story spread on October 19, 2026, when outlets including USA Today and Medical Daily ran headlines about GLP-1 injections recalled nationwide. Here is what was recalled, what the words mean and what to do if you have a vial at home.

Tirzepatide recall 2026: the affected products

These are the fall 2026 recalls, as reported from FDA enforcement reports.

The FDA reason for every GLP-1 product above was "lack of assurance of sterility." Lot numbers and beyond-use dates are in the FDA enforcement report for each event. If your syringe or vial has no lot number, ask the pharmacy that filled it.

Is Zepbound or Mounjaro recalled?

No. Zepbound and Mounjaro are tirzepatide made by Eli Lilly and approved by the FDA. The recalls above are for compounded tirzepatide, which a pharmacy mixes itself. The FDA does not review compounded drugs for safety, quality or effectiveness before they are sold.

An easy check: if your box says Zepbound or Mounjaro and you got it from a licensed pharmacy or LillyDirect, these recalls do not apply to you. If your label shows a pharmacy name, a mixed formula (such as "with B12" or "with niacinamide") or a strength in mg/mL drawn from a vial, it is compounded. Our Mounjaro guide explains the brand-name drug.

Why was compounded tirzepatide recalled?

"Lack of assurance of sterility" means the pharmacy could not show its injections were made in clean enough conditions. An injection goes under your skin, so germs in a vial can cause an infection.

Medical Daily reviewed the FDA inspection report (Form 483) for Houston RX. Inspectors were on site from August 20 to 28, 2026, and listed 14 observations. Among them:

• Microbial growth was found in a clean hood on August 3 after a tirzepatide and niacinamide lot was filled. That lot was still released.
• A ceiling vent near the cleanroom had water stains and what looked like mold.
• Some active ingredients came with certificates marked "for research and development" only.

A Form 483 lists what inspectors saw. It is not the FDA's final decision. Apothecary Pharma had already received an FDA warning letter in December 2025, according to the MedShadow Foundation.

What does a Class II recall mean?

The FDA sorts recalls into three classes.

So Class II is the middle level. It does not mean the vials are proven contaminated. It means the FDA could not be sure they were safe, which is a good enough reason not to inject them.

What to do if you have recalled tirzepatide

1. Check the label. Look for the pharmacy name, the strength and the lot number. Compare them with the FDA enforcement report, or ask your prescriber which pharmacy filled your order.
2. Do not inject a recalled vial. Call your prescriber before your next dose. Do not change, stretch or skip doses on your own. Ask how to restart safely with a product from another source.
3. Keep the vial and box. The pharmacy or the FDA may want the lot details.
4. Watch for infection. Spreading redness, heat, swelling, pus or worse pain at the injection site needs a call to your doctor. Fever, chills, a racing heart or confusion after a shot needs urgent care.
5. Report problems. You or your doctor can file a report with FDA MedWatch.

Our guide to injection site reactions shows what is normal and what is not.

Earlier tirzepatide recalls

These are not the first. The FDA's public recall database (openFDA) shows earlier compounded tirzepatide recalls for the same reason:

The FDA also says it has received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026. It notes that the real number is likely higher, because many pharmacies are not required to report. Reports alone do not prove the drug caused the problem.

Will this change your treatment plan?

That is a talk to have with your prescriber. Some people switch to brand-name tirzepatide through insurance or a maker's self-pay program. Our GLP-1 cost and coverage guide explains the options, and our compounded GLP-1 guide covers how to judge a pharmacy.

A pause between doses can also bring back hunger. Keep eating enough protein and keep up your strength work while you sort it out, so the weight you lose stays fat and not muscle. Sharpy gives you one protein target, one 20-minute workout and one Shape Score each day, whichever medicine you end up on. Our protein target guide shows how much you need.

The bottom line

The tirzepatide recall news covers compounded vials and syringes from three pharmacies, not Zepbound or Mounjaro. All three are Class II, for sterility concerns, with no illnesses publicly linked so far. Check your label, do not inject a recalled product and call your prescriber about next steps. Then let Sharpy help you protect your muscle while you get back on track.

Sources

• FDA Recalls and Warnings: Sterility Issues With Compounded GLP-1s, MedShadow Foundation, October 16, 2026
• Houston Pharmacy Behind Recalled Compounded Tirzepatide Vials Drew 14 FDA Inspection Observations, Medical Daily, October 19, 2026
• FDA Enforcement Reports
• Recalls Background and Definitions, FDA
• FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA (updated October 1, 2026)
• Drug recall enforcement reports (ProRx, New Life Pharma), openFDA
• MedWatch: FDA Safety Information and Adverse Event Reporting Program